Study of CYR-101 in Patients With Schizophrenia

Summary

This Phase II study will test whether CYR-101, a CNS-active compound with novel pharmacological profile and devoid of dopamine D2 receptor binding properties, is efficacious when administered orally in the management of patients with a diagnosis of DSM-IV schizophrenia.

Timeline

Start

2008-03

Primary completion

2010-05

Completion

2010-06

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

release “In a Phase 2a, placebo-controlled trial, clinically significant improvement of negative symptoms that continuously improved over time was observed after three months of administering MIN-101” minervaneurosciences.com ↗

Drugs

Indications